Vasoactive intestinal peptide: Cardiovascular effects

Cardiovascular Research

Volumn 49, Issue 1, 2001, Pages 27-37

  Henning, Robert J ^a,b   Sawmiller, Darrell R ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b James A Haley Veterans Hospital   (United States)

Author keywords

Contractile function; Coronary circulation; Heart rate (variability); Neurotransmitters; Vasoconstriction dilation

Indexed keywords

ACETYLCHOLINE; ADENYLATE CYCLASE; CHOLINERGIC RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; NERVE GROWTH FACTOR; NORADRENALIN; PROSTAGLANDIN D; PROSTAGLANDIN E; SEROTONIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

BLOOD VESSEL TONE; CARDIOVASCULAR EFFECT; CHOLINERGIC STIMULATION; CORONARY ARTERY BLOOD FLOW; CORONARY VASCULAR RESISTANCE; DRUG POTENCY; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE REPERFUSION; HEART RATE; HORMONE RELEASE; HUMAN; INOTROPISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; VAGUS NERVE STIMULATION; VASOCONSTRICTION; VASODILATATION;

ANIMALS; CORONARY CIRCULATION; HEART RATE; HUMANS; MYOCARDIAL CONTRACTION; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; VASOACTIVE INTESTINAL PEPTIDE; VASODILATION;

EID: 0034749277     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(00)00229-7     Document Type: Review

References (130)

1. Polypeptide with broad biological activity: Isolation from small intestine
2. Potent peripheral and splanchnic vasodilator peptide from normal gut
3. Structure of the porcine vasoactive intestinal octacosapeptide. The amino acid sequence. Use of kallikrein in its determination
4. Biological activities of synthetic peptides corresponding to fragments of and to the entire sequence of the vasoactive intestinal peptide
5. VIP - A 'very important peptide' in the sympathetic nervous system?
6. Role of VIP, PACAP, and related peptides in the regulation of the hypothalamo-pituitary-adrenal axis
7. The complete structure of the rat VIP gene
8. Sequential expression in the nervous system of c-myb and VIP genes, located in human chromosomal region 6q24
9. Structure and expression of the vasoactive intestinal peptide (VIP) gene in a human tumor
10. Vasoactive intestinal polypeptide: Measurement, distribution and putative neurotransmitter function
11. VIP and autonomic neurotransmission
12. Vasoactive intestinal peptide receptors in pancreas and liver: Structure-function relationship
13. Vasoactive intestinal peptide as a mediator of intercellular communication in the cerebral cortex
14. Pharmaceutical VIP: Prospects and problems
15. Localization of vasoactive intestinal polypeptide (VIP) to central and peripheral neurons
16. Axonal transport of neuropeptides in the cervical vagus nerve of the rat
17. Characteristics of the axonal transport of vasoactive intestinal polypeptide (VIP) in nerves of the cat
18. Vasoactive intestinal polypeptide in the pig pancreas: Role of VIPergic nerves in control of fluid and bicarbonate secretion
19. Vasoactive intestinal polypeptide in cholinergic neurons of exocrine glands: Functional significance of coexisting transmitters for vasodilation and secretion
20. Vasoactive intestinal peptide (VIP). Current Status
21. Neurobiological and neuroendocrine functions of the vasoactive intestinal peptide (VIP)
22. Secretin and vasoactive intestinal peptide receptors: Members of a unique family of G protein-coupled receptors
23. XVII Normenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide
24. Vasoactive intestinal peptide receptor in failing human ventricular myocardium exhibits increased affinity and decreased density
25. VIP receptors in mesenteric and coronary arteries: A radioligand binding study
26. Comparative study of vascular relaxation and receptor binding by PACAP and VIP
27. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor
28. Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor
29. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions
30. Rat aortic smooth muscle cell proliferation is bidirectionally regulated in a cell cycle-dependent manner via PACAP/VIP type 2 receptor
31. Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: Implications for their role in human physiology
32. Effects of vasoactive intestinal polypeptide, monoamines, prostaglandins, and 2-chloroadenosine on adenylate cyclase in rat cerebral microvessels
33. Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium derived relaxing factor in the cat
34. Functional receptors for vasoactive intestinal peptide in cultured vascular smooth muscle cells from rat aorta
35. Effect of vasoactive intestinal polypeptide (VIP) on cyclic AMP level and relaxation in rat isolated aorta
36. Vasoactive intestinal peptide evokes endothelium dependent relaxation and cyclic AMP accumulation in rat aorta
37. Secretin and VIP stimulated adenylate cyclase from rat heart. 1. General properties and structural requirements for enzyme activation
38. Vasoactive intestinal peptide (VIP) and peptide having N-terminal histidine and C-terminal isoleucine amide (PHI) stimulate adenylate cyclase activity in human heart membranes
39. Secretin and vasoactive intestinal peptide are potent stimulants of cellular contraction and accumulation of cyclic AMP in rat ventricular cardiomyocytes
40. Pituitary adenylate cyclase-activating polypeptide stimulates cardiodilatin/atrial natriuretic peptide (CDD/ANP-(99-126) secretion from cultured neonatal rat myocardiocytes
41. Vasoactive intestinal peptide: Vasodilatation and cyclic AMP generation
42. Mechanisms of vasodilation induced by vasoactive intestinal polypeptide in rabbit mesenteric artery
43. Vasoactive intestinal polypeptide-sensitive cyclic adenosine monophosphate generating system in the rat portal vein
44. Vascular effects and cyclic AMP production produced by VIP, PHM, PHV, PACAP-27, PACAP-38 and NPY on rabbit ovarian artery
45. Topographical distribution of the secretin- and VIP-stimulated adenylate cyclase system in the heart of five animal species
46. Cerebral vascular adenylate cyclase: Evidence for coupling to receptors for vasoactive intestinal peptide and parathyroid hormone
47. Cyclic AMP and mechanisms of vasodilation
48. Endothelial dependent relaxant effects of vasoactive intestinal polypeptide and arachidonic acid in rat aortic strips
49. Mechanisms of endothelium-dependent vascular smooth muscle relaxation elicited by bradykinin and VIP
50. Predominant role for nitric oxide in the relaxation induced by vasoactive intestinal polypeptide in human uterine artery
51. Cyclic nucleotide crosstalk and the regulation of cerebral vasodilation
52. Vasoactive intestinal peptide as a neurotransmitter in the cerebral circulation
53. Effects of peptides and non-peptides on isolated arterial smooth muscles: Role of endothelium
54. Vasoactive intestinal peptide may participate in the vasodilation of the dog hepatic artery
55. Effect of mechanical stimulation, substance P and vasoactive intestinal polypeptide on the electrical and mechanical activities of circular smooth muscle from pig coronary arteries contracted with acetylcholine: Role of endothelium
56. Hyperpolarizing vasodilators activate ATP-sensitive K+ channels in arterial smooth muscle
57. The mechanisms of the relaxation induced by vasoactive intestinal peptide in the porcine coronary artery
58. Hyperpolarization and relaxation of canine vascular smooth muscle to vasoactive intestinal polypeptide
59. Relaxation of isolated gastric smooth muscle cells by vasoactive intestinal peptide
60. Activation of distinct cAMP- and cGMP-dependent pathways by relaxant agents in isolated gastric muscle cells
61. Selective expression of vasoactive intestinal peptide (VIP)2/pituitary adenylate cyclase-activating polypeptide (PACAP)3 receptors in rabbit and guinea pig gastric and tenia coli smooth muscle cells
62. G protein-dependent activation of smooth muscle eNOS via natriuretic peptide clearance receptor
63. Regulation of the vasoactive intestinal peptide receptor
64. Interplay between inotropic and lusitropic effects of cyclic adenosine monophosphate on the myocardial cell
65. VIP and secretin augment cardiac L-type calcium channel current in isolated adult rat ventricular myocytes
66. Activation of the hyperpolarization-activated current (if) in sino-atrial node myocytes of the rabbit by vasoactive intestinal peptide
67. Actions of vasoactive intestinal peptide and neuropeptide Y on the pacemaker current in canine Purkinje fibers
68. Heart receptors for VIP, PHI and secretin are able to activate adenylate cyclase and to mediate inotropic and chronotropic effects. Species variations and pathophysiology
69. Secretin and VIP-stimulated adenylate cyclase from rat heart. II Impairment in spontaneous hypertension
70. Impairment of hormone-stimulated cardiac adenylate cyclase activity in the genetically obese (fa/fa) Zucker rat
71. Vasoactive intestinal peptide fluctuates in human blood with a circadian rhythm
72. The plasma vasoactive intestinal peptide (VIP) response to exercise is increased after prolonged strain, sleep and energy deficiency and extinguished by glucose infusion
73. Vasoactive intestinal peptide in man: Pharmacokinetics, metabolic and circulatory effects
74. Radioimmuoassay of vasoactive intestinal polypeptide in plasma
75. Biological actions of vasoactive intestinal peptide in man
76. Vasoactive intestinal polypeptide: Abundant immunoreactivity in neural cell lines and normal nervous tissue
77. Vasoactive intestinal peptide and watery-diarrhoea syndrome
78. Release of vasoactive intestinal peptide and neuropeptide Y from canine heart
79. Coronary vasodilator action of VIP
80. Distribution of vasoactive intestinal polypeptide like immunoreactivity in the mammalian heart. Interrelation with neurotensin- and substance P-like immunoreactive nerves
81. VIP and NPY in canine hearts, Distribution and effect of total and selective parasympathetic denervation
82. Action and localization of vasoactive intestinal peptide in the coronary circulation: Evidence for nonadrenergic, noncholinergic coronary regulation
83. Action of vasoactive intestinal peptide and distribution of its binding sites in vessels used for coronary artery bypass grafts
84. Effect of vasoactive intestinal polypeptide on the canine cardiovascular system
85. Vasoactive intestinal peptide in the heart
86. Relaxation of isolated bovine coronary arteries by vasoactive intestinal peptide
87. Presence and actions of vasoactive intestinal peptide in the isolated rabbit heart
88. Direct coronary vasodilation induced by intracoronary vasoactive intestinal peptide
89. Effect of vasoactive intestinal peptide on myocardial contractility and coronary blood flow in the dog: Comparison with isoproterenol and forskolin
90. Coronary hemodynamic effects of intravenous vasoactive intestinal peptide in humans
91. Vagal nerve stimulation releases vasoactive intestinal peptide which significantly increases coronary artery blood flow
92. Vagal nerve stimulation during muscarinic and β-adrenergic blockade causes significant coronary artery dilation
93. 17]VIP
94. Vasoactive intestinal peptide (VIP) as transmitter of inhibitory motor neurons of the gut: Evidence from the use of selective VIP antagonists and VIP antiserum
95. Myocardial and gastrointestinal release of vasoactive intestinal peptide during experimental acute myocardial infarction
96. Protective role of intracoronary vasoactive intestinal peptide in ischemic and reperfused myocardium
97. Coordinated role of vasoactive intestinal peptide and nitric oxide in cardioprotection
98. Vasoactive intestinal peptide, a singlet oxygen quencher
99. Elevated levels of plasma vasoactive intestinal peptide in human acute myocardial infarction
100. Effect of age and relation to mortality on serial changes of vasoactive intestinal peptide in acute myocardial infarction
101. Effects of acetylcholine and vasoactive intestinal polypeptide on cerebral blood flow
102. Vasoactive intestinal polypeptide (VIP): Effects in the eye and on regional blood flows
103. Distribution of vasoactive intestinal peptide and its receptors in the arteries of the rabbit
104. Complementary role of vasoactive intestinal polypeptide (VIP) and acetylcholine for cat submandibular gland blood flow and secretion. I. VIP release
105. Nervous release of vasoactive intestinal polypeptide from the feline uterus: Pharmacological characteristics
106. Beneficial influence of vasoactive intestinal peptide on ventriculovascular coupling in closed-chest dogs
107. Influence of vasoactive intestinal polypeptide (VIP) on splanchnic and central hemodynamics in healthy subjects
108. Contractile effects of cardiac neuropeptides in isolated canine atrial and ventricular muscles
109. The in vitro chronotropic and inotropic effects of vasoactive intestinal peptide (VIP) on the atria and ventricular papillary muscle from the Cynomolgus monkey heart
110. Inotropic responsiveness in hypertensive left ventricular hypertrophy: Impaired inotropic response to glucagon and vasoactive intestinal peptide in renal hypertensive rats
111. Cardiac responses to VIP and VIP-ergic-cholinergic interaction in isolated dog heart preparations
112. Cardiovascular effects of vasoactive intestinal peptide in healthy subjects
113. Desensitization of myocardial but not coronary VIP receptor-mediated responses in dogs
114. Vagal stimulation during muscarinic and β-adrenergic blockade increases atrial contractility and heart rate
115. Vagal nerve stimulation increases right ventricular contraction and relaxation and heart rate
116. Vasoactive intestinal peptide in canine hearts: Effect of total cardiac denervation
117. Human and canine ventricular vasoactive intestinal polypeptide: Decrease with heart failure
118. Vasoactive intestinal peptide in shock and heart failure
119. Vasoactive intestinal peptide in sepsis and shock
120. Vasoactive intestinal peptide in heart failure
121. Peptidergic innervation of the mammalian sinus nodes: Vasoactive intestinal polypeptide, neurotensin, substance P
122. Effects of neuropeptides on heart rate in dogs: Comparison of VIP, PHI, NPY, CGRP, and NT
123. Excess tachycardia: Heart rate after antimuscarinic agents in conscious dogs
124. Myocardial electrophysiological effects of vasoactive intestinal peptide in dogs
125. Effects of vasoactive intestinal polypeptide on heart rate in relation to vagal cardioacceleration in conscious dogs
126. Vasoactive intestinal polypeptide facilitates atrioventricular nodal conduction and shortens atrial and ventricular refractory periods in conscious and anesthetized dogs
127. Electrophysiological effects of vasoactive intestinal peptide in rabbit atrium: A modulation of acetylcholine activity
128. Vasoactive intestinal polypeptide antagonists attenuate vagally induced tachycardia in the anesthetized dog
129. Frequency dependence of vasoactive intestinal polypeptide release and vagally induced tachycardia in the canine heart
130. Postvagal tachycardia